Relx (LON:REL)‘s stock had its “sell” rating reiterated by equities research analysts at UBS Group in a research note issued to investors on Friday, investing.thisismoney.co.uk reports.
A number of other research analysts have also issued reports on the stock. Barclays upgraded shares of Relx to an “overweight” rating and upped their price target for the company from GBX 1,615 ($21.10) to GBX 1,740 ($22.74) in a research note on Monday, September 24th. Citigroup restated a “neutral” rating on shares of Relx in a research note on Wednesday, July 25th. Numis Securities restated a “hold” rating on shares of Relx in a research note on Thursday, July 26th. Liberum Capital restated a “buy” rating on shares of Relx in a research note on Thursday, July 26th. Finally, Berenberg Bank restated a “buy” rating and set a GBX 1,800 ($23.52) price target on shares of Relx in a research note on Monday, October 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of GBX 1,756.07 ($22.95).
LON REL opened at GBX 1,512.50 ($19.76) on Friday. Relx has a 52 week low of GBX 1,399 ($18.28) and a 52 week high of GBX 1,784 ($23.31).
RELX PLC provides information and analytics for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals.
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.